Unmet need in heavily pre-treated patients with HR+/HER2-metastatic breast cancer (mBC) in the US: A ConcertAI analysis

被引：1

作者：

Waks, A. G. ^{[1
]}

Gharaibeh, M. ^{[2
]}

Sjekloca, N. ^{[3
]}

Poluparthi, N. ^{[2
]}

Shah, A. ^{[2
]}

Bergamaco, E. ^{[4
]}

MacCannell, T. ^{[2
]}

Leung, G. ^{[5
]}

Ntalla, I. ^{[6
]}

Oko-osi, H. ^{[2
]}

Tolaney, S. M. ^{[1
]}

机构：

[1] Dana Farber Canc Inst, Med Oncol, Boston, MA USA

[2] Gilead Sci Inc, Dept Hlth Econ & Outcomes Res, Foster City, CA USA

[3] Gilead Sci Europe Ltd, Dept Med Affairs, Stockley Pk, CA USA

[4] Gilead Sci Inc, Dept Med Affairs, Foster City, CA USA

[5] Gilead Sci Inc, Dept Real World Evidence, Foster City, CA USA

[6] Gilead Sci Europe Ltd, Dept Real World Evidence, Stockley Pk, CA USA

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期

关键词：

D O I：

10.1016/j.annonc.2022.07.292

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

253P

引用

页码：S653 / S653

页数：1

共 50 条

[31] HEALTHCARE COSTS IN WOMEN WITH HR+/HER2-METASTATIC BREAST CANCER TREATED WITH CDK4/6 INHIBITORS
Burne, R.
Balu, S.
Guerin, A.
Liang, Y.
Schloessmann, R.
Bungay, R.
Paul, M. L.
VALUE IN HEALTH, 2020, 23 : S44 - S44
[32] Treatment patterns and resource utilization among elderly Medicare patients with HR+/HER2-metastatic breast cancer
Goyal, R. K.
Carter, G. C.
Nagar, S. N.
Smyth, E. N.
Price, G. L.
Huang, Y-J
Bromund, J. L.
Li, L.
Schilder, J. M.
Davis, K. L.
Kaye, J. A.
CANCER RESEARCH, 2017, 77
[33] Observational study of HR+/HER2-metastatic breast cancer patients treated with abemaciclib in Spain in the Named Patient Use Program (AbemusS)
Blanch, Salvador
Gil-Gil, Juan Miguel
Arumi, Miriam
Aguirre, Elena
Segui, Miguel Angel
Atienza, Manuel
Diaz-Cerezo, Silvia
Molero, Alberto
Cervera, Jose Manuel
Gavila, Joaquin
CLINICAL & TRANSLATIONAL ONCOLOGY, 2023, 25 (10): : 2950 - 2959
[34] nextMONARCH: Final overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with HR+, HER2-metastatic breast cancer
Hamilton, E. P.
Cortes, J.
Ozyilkan, O.
Chen, S-C.
Petrakova, K.
Manikhas, A.
Jerusalem, G.
Hegg, R.
Huober, J.
Chapman, S. C.
Yang, Z.
Chen, Y.
Johnston, E. L.
Martin, M.
ANNALS OF ONCOLOGY, 2020, 31 : S348 - S348
[35] Everolimus in heavily pre-treated metastatic breast cancer (MBC): Is real (developing) world experience different?
Bajpai, J.
Ramaswamy, A.
Ghosh, J.
Gulia, S.
Gupta, S.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S292 - S292
[36] Safety profile and activity of lower capecitabine dose in chemionaive and heavily pre-treated patients with metastatic breast cancer (MBC)
Rossi, D.
Alessandroni, P.
Catalano, V
Giordani, P.
Baldelli, A. M.
Luzi, Fedeli S.
Fedeli, A.
Casadei, V
Ceccolini, M.
Tamburrano, T.
Catalano, G.
ANNALS OF ONCOLOGY, 2006, 17 : XI11 - XI11
[37] nextMONARCH: Final overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with HR+, Her2-metastatic breast cancer
Huober, J.
Hamilton, E.
Cortes, J.
Ozyilkan, O.
Chen, S. C.
Petrakova, K.
Manikhas, A.
Jerusalem, G.
Hegg, R.
Chapman, S.
Yang, Z.
Chen, Y.
Johnston, E.
Martin, M.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 244 - 245
[38] Increased survival for heavily pre-treated metastatic breast cancer
Siddall, Rhonda
BRITISH JOURNAL OF HOSPITAL MEDICINE, 2010, 71 (07) : 370 - 370
[39] TREATMENT WITH ERIBULIN (HALAVEN) IN HEAVILY PRE-TREATED PATIENTS WITH METASTATIC BREAST CANCER
Lynge, M.
Liposits, G. I.
Linnet, S.
Langkjer, S. T.
BREAST, 2013, 22 : S43 - S43
[40] Treatment with eribulin (halaven) in heavily pre-treated patients with metastatic breast cancer
Rasmussen, Maja Lynge
Liposits, Gabor
Yogendram, Subethini
Jensen, Anders Bonde
Linnet, Soren
Langkjer, Sven Tyge
ACTA ONCOLOGICA, 2014, 53 (09) : 1275 - +

← 1 2 3 4 5 →